AbbVie Inc.
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$288.84−6.05 (-2.05%)
Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%
AbbVie Europe by Year
Europe ($M) ($M)
AbbVie Europe: $1,804M in FY2025, up 21.5% from a year earlier. That is the highest of the 11 years on record here.
Latest, FY2025
1,804
Period ended Dec 31, 2025
Change on a year earlier
+21.5%
1,485 in FY2024
History
11 years
Since FY2015
Sources
10
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-20) ↗
Reported in Form 10-K Note 16 Segment & Geographic Information.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Europe ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1,804 | +21.5% | Form 10-K (filed 2026-02-20) ↗ |
| FY2024 | Dec 31, 2024 | 1,485 | +3.6% | Form 10-K (filed 2026-02-20) ↗ |
| FY2023 | Dec 31, 2023 | 1,433 | +4.7% | Form 10-K (filed 2025-02-14) ↗ |
| FY2022 | Dec 31, 2022 | 1,369 | -2.2% | Form 10-K (filed 2024-02-20) ↗ |
| FY2021 | Dec 31, 2021 | 1,400 | -8.7% | Form 10-K (filed 2023-02-17) ↗ |
| FY2020 | Dec 31, 2020 | 1,534 | +137.5% | Form 10-K (filed 2022-02-18) ↗ |
| FY2019 | Dec 31, 2019 | 646 | +7.8% | Form 10-K (filed 2021-02-19) ↗ |
| FY2018 | Dec 31, 2018 | 599 | -3.5% | Form 10-K (filed 2020-02-21) ↗ |
| FY2017 | Dec 31, 2017 | 621 | +23.2% | Form 10-K (filed 2019-02-27) ↗ |
| FY2016 | Dec 31, 2016 | 504 | -1.8% | Form 10-K (filed 2018-02-16) ↗ |
| FY2015 | Dec 31, 2015 | 513 | – | Form 10-K (filed 2017-02-17) ↗ |
Cite this data
StockData. (2026). AbbVie Europe ($M), annual FY2015–FY2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/geo-lla-eur
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.